Boston Scientific (BSX) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The OPTION-EMEA Clinical Trial, officially titled “Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation – Europe, Middle East and Africa [OPTION-EMEA],” aims to track real world outcomes for patients with atrial fibrillation treated with Boston Scientific’s systems in one combined procedure. It matters because it tests whether doing both treatments together is practical and safe in everyday hospital settings.
The study evaluates a combined approach using the FARAPULSE PFA System and the WATCHMAN FLX Pro or WATCHMAN FLX devices. The goal is to control irregular heart rhythm and reduce stroke risk in one visit instead of two separate procedures.
The trial is an interventional, single arm study with all enrolled patients receiving the same combined treatment. There is no randomization or blinding, and the main aim is to collect outcome and safety data rather than to compare products head to head.
The study was first submitted on January 9, 2026, marking the formal launch of the project within the regulatory system. The most recent update was filed on February 14, 2026, showing that the protocol is active and being refined ahead of patient enrollment.
The “Not Yet Recruiting” status means sites are preparing but have not started enrolling patients, so clinical readouts and market-moving data are still some time away. Investors should view this as an early but important step in expanding the post-market evidence base for these AF and stroke prevention tools.
For Boston Scientific (BSX), strong future data from OPTION-EMEA could support wider use of FARAPULSE and WATCHMAN in a single session, reinforcing its position in AF ablation and structural heart markets. This would help the company compete more effectively with device peers pursuing similar combination strategies in rhythm control and stroke prevention.
Near term, the update is unlikely to shift BSX valuation on its own, but it adds to the company’s pipeline of evidence that can support reimbursement and physician adoption. Over time, positive real world findings could translate into higher procedure volumes and a larger recurring revenue base, which the market tends to reward with premium multiples.
The OPTION-EMEA clinical trial is active in setup and has been recently updated, and more detailed information is available on the ClinicalTrials portal.
To learn more about BSX’s potential, visit the Boston Scientific drug pipeline page.